CORRECTION article

Front. Immunol., 08 May 2024

Sec. Immunological Tolerance and Regulation

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1384171

Corrigendum: Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis

  • 1. Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain

  • 2. Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Madrid, Spain

  • 3. Advanced Therapy Unit, Health Research Institute- Fundación Jiménez Díaz, University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain

  • 4. Laboratorio de Reumatología Experimental y Observacional, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain

In the published article, there was a mistake in the Funding statement. The Funding statement for the “Instituto de Salud Carlos III (ISCIII)” was displayed as “Instituto de Salud Carlos III (ISCIII)” (PIE15/00048, PI17/01161, PI21/01441, PI20/01266, RICORS; RD21/0017/00’.

The correct statement is as follows:

‘This work was supported by grants from “Instituto de Salud Carlos III (ISCIII)”, co-funded by the European Union (PIE15/00048, PI17/01161, PI21/01441, PI20/01266, RICORS; RD21/0017/00; funded by European Union-NextGenerationEU. Plan de Recuperación Transformación y siliencia) and Comunidad de Madrid (AvanCell, B2017/BMD-3692). CIBERER is an initiative of the “Instituto de Salud Carlos III” and the European Regional Development Fund (ERDF)’.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

mesenchymal stem/stromal cell-based therapy, K/BxN serum transfer-induced arthritis, joint inflammation, cell therapy, immunomodulation

Citation

Lopez-Santalla M, Conde C, Rodriguez-Trillo A and Garin MI (2024) Corrigendum: Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis. Front. Immunol. 15:1384171. doi: 10.3389/fimmu.2024.1384171

Received

08 February 2024

Accepted

26 April 2024

Published

08 May 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

15 - 2024

Updates

Copyright

*Correspondence: Marina I. Garin, ; Mercedes Lopez-Santalla,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics